These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15269569)

  • 1. Aggressive lowering of low-density lipoprotein cholesterol: do the studies apply to the elderly?
    DeSilvey DL
    Am J Geriatr Cardiol; 2004; 13(4):217-8. PubMed ID: 15269569
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):85-6. PubMed ID: 15727720
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein levels and outcomes after statin therapy.
    Clearfield M
    Curr Atheroscler Rep; 2006 Jan; 8(1):8-9. PubMed ID: 16455006
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Ghali JK
    Am J Cardiol; 1998 Sep; 82(5):703. PubMed ID: 9732912
    [No Abstract]   [Full Text] [Related]  

  • 6. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 8. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
    Cannon CP; McCabe CH; Belder R; Breen J; Braunwald E
    Am J Cardiol; 2002 Apr; 89(7):860-1. PubMed ID: 11909576
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
    Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
    Correia LC; Spósito AC; Lima JC; Magalhães LP; Passos LC; Rocha MS; D'Oliveira A; Esteves JP
    Am J Cardiol; 2003 Aug; 92(3):298-301. PubMed ID: 12888137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering therapy in acute coronary syndromes.
    Sacks FM
    JAMA; 2001 Apr; 285(13):1758-60. PubMed ID: 11277832
    [No Abstract]   [Full Text] [Related]  

  • 12. Cholesterol limbo: How low should the bar go. Ratcheting down LDL to extra-low levels with high-dose statins seems to work wonders.
    Harv Health Lett; 2004 May; 29(7):1-2. PubMed ID: 15153394
    [No Abstract]   [Full Text] [Related]  

  • 13. "Major surprise" in a new study means likely changes in treatment.
    Heart Advis; 2004 May; 7(5):2. PubMed ID: 15195616
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Schwartz GG; Oliver MF; Ezekowitz MD; Ganz P; Waters D; Kane JP; Texter M; Pressler ML; Black D; Chaitman BR; Olsson AG
    Am J Cardiol; 1998 Mar; 81(5):578-81. PubMed ID: 9514453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can early treatment with atorvastatin (Lipitor) improve the outcome of patients with acute coronary syndromes?
    Johnson K; Breen WJ
    J Fam Pract; 2001 Jul; 50(7):572. PubMed ID: 11485701
    [No Abstract]   [Full Text] [Related]  

  • 16. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
    Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
    Kanadaşi M; Cayli M; Demirtaş M; Inal T; Demir M; Koç M; Avkaroğullari M; Dönmez Y; Usal A; Alhan CC; San M
    Heart Vessels; 2006 Sep; 21(5):291-7. PubMed ID: 17151816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.